WO2025088546 - FC DOMAIN VARIANTS WITH ENHANCED FC RECEPTOR BINDING
National phase entry:
Publication Number
WO/2025/088546
Publication Date
01.05.2025
International Application No.
PCT/IB2024/060489
International Filing Date
24.10.2024
Title **
[English]
FC DOMAIN VARIANTS WITH ENHANCED FC RECEPTOR BINDING
[French]
VARIANTS DE DOMAINE FC AVEC LIAISON DE RÉCEPTEUR FC AMÉLIORÉE
Applicants **
ABLYNX N.V.
Inventors
JAWORSKI, Julie A.
KATHURIA, Sagar V.
MACKNESS, Brian
PARK, Sunghae
SUN, Victor Zhao
ZHOU, Qun
Priority Data
63/593,011
25.10.2023
US
63/638,212
24.04.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5793 | |
| EPO | Filing, Examination, Granting | 114392 | |
| Japan | Filing, Examination, Granting | 4869 | |
| South Korea | Filing, Examination, Granting | 8429 | |
| USA | Filing, Examination, Granting | 25640 |
Total:
159,123
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure provides Fc domain variant polypeptides, including effector-competent Fc domain variants. The present disclosure also provides Fc domain variant polypeptides comprising at least one substitution or at least two substitutions at amino acid positions 251, 267, 268, 298, 314, 330, 339, 373, and 376, according to EU numbering, as compared to a Fc domain parent polypeptide. The present disclosure also provides nucleic acids encoding Fc domain variant polypeptides and host cells for making Fc domain variant polypeptides. Methods for increasing the yield of Fc domain variant polypeptides, and methods of using Fc domain variant polypeptides to treat disease, are also provided.[French]
La présente divulgation concerne des polypeptides de variants de domaine Fc, comprenant des variants de domaine Fc compétents pour un effecteur. La présente divulgation concerne également des polypeptides de variants de domaine Fc comprenant au moins une substitution ou au moins deux substitutions au niveau des positions d'acides aminés 251, 267, 268, 298, 314, 330, 339, 373 et 376, selon la numérotation EU, par comparaison à un polypeptide parent de domaine Fc. La présente divulgation concerne également des acides nucléiques codant pour des polypeptides de variants de domaine Fc et des cellules hôtes pour la préparation des polypeptides de variants de domaine Fc. La présente divulgation concerne également des procédés d'augmentation du rendement de polypeptides de variants de domaine Fc, et des méthodes d'utilisation de polypeptides de variants de domaine Fc pour traiter une maladie.